The economic burden of guideline-recommended first line care for acute low back pain
- 605 Downloads
To report health care costs and the factors associated with such costs in people with acute low back pain receiving guideline-recommended first line care.
This is a secondary analysis of a trial which found no difference in clinical outcomes. Participants with acute low back pain received reassurance and advice, and either paracetamol (taken regularly or as needed) or placebo for up to 4 weeks and followed up for 12 weeks. Data on health service utilisation were collected by self-report. A health sector perspective was adopted to report all direct costs incurred (in 2015 AUD, 1 AUD = 0.53 Euro). Costs were reported for the entire study cohort and for each group. Various baseline clinical, demographic, work-related and socioeconomic factors were investigated for their association with increased costs using generalised linear models.
The mean cost per participant was AUD167.74 (SD = 427.24) for the entire cohort (n = 1365). Most of these costs were incurred in primary care through visits to a general practitioner or physiotherapist. Compared to the placebo group, there was an increase in cost when paracetamol was taken. Multivariate analysis showed that disability, symptom duration and compensation were associated with costs. Receiving compensation was associated with a twofold increase compared to not receiving compensation.
Taking paracetamol as part of first line care for acute low back pain increased the economic burden. Higher disability, longer symptom duration and receiving compensation were independently associated with increased health care costs.
KeywordsLow back pain Costs and cost analysis Health care costs Paracetamol
Data for this study originated from a clinical trial funded by the National Health and Medical Research Council (NHMRC) of Australia. GlaxoSmithKline Australia provided subsequent supplementary funding and the paracetamol and matched placebo. CL, CW, CM and SJ receive research fellowships from NHMRC. JL received funding from an ARC Future Fellowship. AM is the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing.
Compliance with ethical standards
Conflict of interest
- 1.Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4 CrossRefPubMedCentralGoogle Scholar
- 15.Williams CM, Latimer J, Maher CG, McLachlan AJ, Cooper CW, Hancock MJ, Day RO, McAuley JH, Lin C-WC (2010) PACE—the first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskelet Disord 11:169. doi: 10.1186/1471-2474-11-169 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Organisation for Economic Co-operation and Development Purchasing power parities for GDP and related indicators. http://stats.oecd.org/. Accessed 23 March 2016
- 20.Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin C-WC, Day RO, McLachlan AJ, Ferreira ML (2015) Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 350:h1225. doi: 10.1136/bmj.h1225 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Ferreira ML, Machado G, Latimer J, Maher C, Ferreira PH, Smeets RJ (2010) Factors defining care-seeking in low back pain—a meta-analysis of population based surveys. Eur J Pain 14 (7):747 e741–747. doi: 10.1016/j.ejpain.2009.11.005
- 25.Reeve R, Haas M (2013) Estimating the cost of emergency department presentations in NSW. University of Technology, SydneyGoogle Scholar